No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Actinogen Expects to Reach 100 Enrollments in Alzheimer's Disease Trial by Quarter-End
Actinogen Agrees With US FDA on Trials Required for Marketing Approval of Depressive Disorder Drug Candidate; Shares Rise 3%
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Xanamem: Alzheimer's Breakthrough Set for 2025, 2026
Actinogen Reports Busy 6 Months as Development of Xanamem Molecule Ramps up
Actinogen Medical Ltd: ACW HY25 results Advancing to latestage clinical development